But understanding what happens in your brain during an attack can help manage the condition better and empower them. A ...

Company had $98.8 million in cash as of December 31, 2024; existing cash expected to fund planned operations into the first quarter of 2026 Company is debt-free after repaying mortgage on facilities ...

The U.S. Food and Drug Administration has approved Symbravo (meloxicam and rizatriptan) for the acute treatment of migraine ...

Investors interested in arranging a meeting with the Company’s management during the conference can register on the BIO CEO & Investor Conference website here.

Detailed price information for Tonix Pharm Holdings (TNXP-Q) from The Globe and Mail including charting and trades.

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline ...

An effort two decades in the making, Vertex Pharmaceuticals Inc.’s suzetrigine gained U.S. FDA approval as the first drug targeting the NaV1.8 pain signal. Branded Journavx, the oral small molecule is ...

The approval of Axsome Therapeutics’ Symbravo for migraine with or without aura came alongside the greenlight for Vertex's ...

The Axsome management team will provide an overview of SYMBRAVO and anticipated commercial plans. The presenters will be available to answer questions at the end of the presentation. To access the ...

Propranolol's protective effect was found to be more pronounced in women with migraines without aura and for ischemic stroke. For patients with migraine, the clinical benefits of propranolol ...

Gait training exercises are movements designed to help improve strength, balance and coordination when walking. They may be part of a physical therapy program for a person recovering from a stroke, an ...